| Literature DB >> 33940771 |
Takuya Umehara1,2, Ayaka Inukai2, Daisuke Kuwahara2, Ryo Kaneyashiki2, Akinori Kaneguchi1, Miwako Tsunematsu3, Masayuki Kakehashi3.
Abstract
STUDYEntities:
Keywords: Activity; Collapse; Osteoporotic vertebral fractures; Physical function
Year: 2021 PMID: 33940771 PMCID: PMC9260407 DOI: 10.31616/asj.2020.0285
Source DB: PubMed Journal: Asian Spine J ISSN: 1976-1902
Fig. 1(A–D) Semiquantitative method severity classification.
Fig. 2Flow chart of osteoporotic vertebral fractures patients.
Patient characteristics at admission and 4 weeks after admission
| Time | Variable | Category | Patient | Collapsed group (n=22) | Non-collapsed group (n=24) | |
|---|---|---|---|---|---|---|
| Admission (baseline) | Age (yr) | 81.5±9.4 | 82.5±9.6 | 80.3±9.3 | 0.429 | |
| Sex | Male/female | 9/37 | 5/17 | 4/20 | 0.718 | |
| Body mass index (kg/m2) | 22.2±3.4 | 22.1±2.4 | 22.5±4.1 | 0.682 | ||
| Duration of bed rest after admission (day) | 13.4±9.1 | 14.7±6.9 | 12.2±10.4 | 0.092 | ||
| Hospital walking independence | Presence/absence | 37/9 | 19/3 | 18/6 | 0.464 | |
| Dwelling place | Home/institution | 44/2 | 22/0 | 22/2 | 0.490 | |
| Length of stay (day) | 53.6±18.7 | 50.8±16.0 | 56.2±20.8 | 0.384 | ||
| HDS-R (points) | 23.5±5.9 | 25.0±5.0 | 22.5±6.4 | 0.309 | ||
| Vertebral fracture information | ||||||
| Location of fractures | Th8/Th9/Th11/Th12/L1/L2/L3/L4/L5 | 1/0/4/18/14/5/6/4/2 | 1/1/2/11/7/2/3/3/0 | 0/1/2/7/7/3/3/1/2 | ||
| No. of fractures | 1/2 | 36/10 | 16/6 | 20/4 | 0.484 | |
| Thoracolumbar spine fracture | 31/15 | 17/5 | 14/10 | 0.171 | ||
| MRI intensity ratio | 67.1±26.7 | 63.5±27.9 | 70.4±25.7 | 0.475 | ||
| Degree of fracture (SQ method) | 1.4±0.6 | 1.7±0.7 | 1.0±0.0 | 0.001 | ||
| Vertebral fractures with posterior wall | Presence/absence | 4/42 | 3/19 | 1/23 | 0.336 | |
| Neurological symptoms | Presence/absence | 6/40 | 3/19 | 3/21 | 0.624 | |
| Medical history | ||||||
| Chronic obstructive pulmonary disease | Presence/absence | 1/45 | 0/22 | 1/23 | 0.522 | |
| Cardiovascular disease | Presence/absence | 8/38 | 7/15 | 1/23 | 0.020 | |
| Cerebrovascular disease | Presence/absence | 1/45 | 0/22 | 1/23 | 0.522 | |
| Cancer | Presence/absence | 4/42 | 2/20 | 2/22 | 0.662 | |
| Hypertension | Presence/absence | 12/34 | 7/15 | 5/19 | 0.397 | |
| Diabetes | Presence/absence | 5/41 | 3/19 | 2/21 | 0.665 | |
| Kidney failure | Presence/absence | 0/46 | 0/22 | 0/24 | - | |
| Vertebral fracture | Presence/absence | 21/25 | 11/11 | 10/14 | 0.571 | |
| Pre pharmacotherapy | Presence/absence | 1/45 | 1/21 | 1/23 | 0.478 | |
| Parathyroid hormone | Presence/absence | 0/46 | 0/22 | 0/24 | - | |
| Anti-receptor activator of NF-κB ligand antibody | Presence/absence | 0/46 | 0/22 | 0/24 | - | |
| Bisphosphonate | Presence/absence | 0/46 | 0/22 | 0/24 | - | |
| Selective estrogen receptor modulator | Presence/absence | 0/46 | 0/22 | 0/24 | - | |
| Vitamin D | Presence/absence | 1/45 | 1/21 | 0/24 | 0.478 | |
| Bone metabolism marker | Total P1NP | 55.3±26.5 | 53.8±21.3 | 56.7±31.0 | 0.852 | |
| 25(OH) vitamin D | 14.7±5.9 | 15.0±6.2 | 14.4±5.8 | 0.749 | ||
| TRACP-5b | 459.3±182.0 | 474.3±209.5 | 445.7±156.0 | 0.600 | ||
| GNRI (points) | 95.5±7.1 | 97.0±6.1 | 94.2±7.8 | 0.187 | ||
| PCS (points) | 18.1±11.6 | 16.6±8.8 | 19.4±13.8 | 0.431 | ||
| CSI (points) | 18.6±12.7 | 19.6±11.2 | 17.7±14.1 | 0.301 | ||
| VAS rest (mm) | 1.4±2.1 | 1.4±2.4 | 1.4±1.9 | 0.695 | ||
| VAS activity (mm) | 4.4±2.8 | 4.4±3.1 | 4.4±2.6 | 0.994 | ||
| ADL before admission (points) | 97.9±5.9 | 99.6±6.1 | 96.5±7.7 | 0.091 | ||
| Walking independence before admission (points) | 14.6±1.4 | 15.0±0.0 | 14.1±1.9 | 0.047 | ||
| 4 weeks | Degree of fracture (SQ method) | 1.9±0.9 | 2.5±0.6 | 1.0±0.0 | 0.000 | |
| PCS (points) | 14.6±12.0 | 17.2±13.1 | 12.1±10.6 | 0.190 | ||
| CSI (points) | 15.6±12.1 | 17.6±12.6 | 13.7±11.5 | 0.252 | ||
| VAS rest (mm) | 0.6±1.7 | 0.9±2.3 | 0.4±1.0 | 0.299 | ||
| VAS activity (mm) | 1.9±2.7 | 1.9±2.5 | 1.8±2.8 | 0.571 | ||
| Knee extension strength (Nm/kg) | 92.0±38.4 | 96.1±43.3 | 86.4±33.3 | 0.281 | ||
| One leg standing movement control (points) | 0.8±0.6 | 1.0±0.7 | 0.5±0.5 | 0.021 | ||
| QOL (points) | 124.3±16.8 | 124.6±18.0 | 124.2±15.9 | 0.939 | ||
| ADL (points) | 83.0±20.1 | 84.6±23.1 | 81.7±17.2 | 0.188 | ||
| Walking independence (points) | 12.3±4.1 | 12.3±4.6 | 12.3±3.9 | 0.779 | ||
Values are presented as mean±standard deviation or number, unless otherwise stated.
HDS-R, Revised Hasegawa’s Dementia Scale; MRI, magnetic resonance imaging; SQ, semiquantitative; NF-κB, nuclear factor-κB; 25(OH) vitamin D, 25-hydroxy vitamin D; TRACP-5b, tartrate-resistant acid phosphatase 5b; GNRI, Geriatric Nutritional Risk Index; PCS, Pain Catastrophizing Scale; CSI, Central Sensitization Inventory; VAS, Visual Analog Scale; ADL, Activities of Daily Living; QOL, quality of life.
Univariable logistic regression analysis
| Variable | Partial regression coefficient | OR (95% CI) | |
|---|---|---|---|
| Admission (baseline) | |||
| Age (yr) | −0.026 | 0.974 (0.915–1.038) | 0.422 |
| Sex | 0.386 | 1.471 (0.340–6.365) | 0.606 |
| Body mass index (kg/m2) | −0.037 | 0.964 (0.809–1.149) | 0.681 |
| Duration of bed rest after admission (day) | 0.032 | 1.032 (0.966–1.103) | 0.348 |
| Hospital walking independence | 0.059 | 1.061 (0.980–1.147) | 0.143 |
| Dwelling place | - | - | - |
| Length of stay (day) | −0.016 | 0.984 (0.952–1.017) | 0.339 |
| HDS-R (points) | 0.067 | 1.070 (0.962–1.189) | 0.212 |
| Vertebral fracture information | |||
| Location of fractures | - | - | - |
| No. of fractures | 0.629 | 1.875 (0.451–7.802) | 0.388 |
| Thoracolumbar spine fracture | 0.887 | 2.429 (0.671–8.784) | 0.176 |
| MRI intensity ratio | −0.010 | 0.990 (0.968–1.012) | 0.377 |
| Degree of fracture (SQ method) | - | - | - |
| Vertebral fractures with posterior wall | 1.290 | 3.632 (0.349–37.826) | 0.281 |
| Neurological symptoms | 0.100 | 1.105 (0.199–6.150) | 0.909 |
| Medical history | |||
| Chronic obstructive pulmonary disease | - | - | - |
| Cardiovascular disease | 2.373 | 10.733 (1.197–96.283) | 0.034 |
| Cerebrovascular disease | - | - | - |
| Cancer | 0.095 | 1.100 (0.141–8.556) | 0.927 |
| Hypertension | 0.573 | 1.773 (0.468–6.721) | 0.399 |
| Diabetes | 0.506 | 1.658 (0.250–11.016) | 0.601 |
| Kidney failure | - | - | - |
| Vertebral fracture | 0.336 | 1.400 (0.437–4.488) | 0.571 |
| Pre-pharmacotherapy | |||
| Parathyroid hormone | - | - | - |
| Anti-receptor activator of NF-κB ligand antibody | - | - | - |
| Bisphosphonate | - | - | - |
| Selective estrogen receptor modulator | - | - | - |
| Vitamin D | - | - | - |
| Total P1NP | −0.004 | 0.996 (0.974–1.018) | 0.707 |
| 25(OH) vitamin D | 0.017 | 1.017 (0.921–1.123) | 0.743 |
| TRACP-5b | 0.001 | 1.001 (0.998–1.004) | 0.591 |
| GNRI (points) | 0.059 | 1.060 (0.972–1.157) | 0.187 |
| PCS (points) | −0.021 | 0.979 (0.930–1.031) | 0.422 |
| CSI (points) | 0.012 | 1.012 (0.966–1.060) | 0.606 |
| VAS rest (mm) | −0.019 | 0.981 (0.747–1.289) | 0.892 |
| VAS activity (mm) | −0.001 | 0.999 (0.812–1.229) | 0.993 |
| ADL before admission (points) | 0.143 | 1.153 (0.957–1.390) | 0.134 |
| Walking independence before admission (points) | - | - | - |
| 4 weeks | |||
| Degree of fracture (SQ method) | - | - | - |
| PCS (points) | 0.037 | 1.037 (0.985–1.092) | 0.162 |
| CSI (points) | 0.028 | 1.029 (0.978–1.082) | 0.273 |
| VAS rest (mm) | 0.210 | 1.234 (0.806–1.888) | 0.333 |
| VAS activity (mm) | 0.016 | 1.016 (0.816–1.266) | 0.887 |
| Knee extension strength (Nm/kg) | 0.007 | 1.007 (0.991–1.023) | 0.390 |
| One leg standing movement control (points) | 1.284 | 3.610 (1.219–10.687) | 0.020 |
| QOL (points) | 0.001 | 1.001 (0.967–1.037) | 0.938 |
| ADL (points) | 0.007 | 1.007 (0.978–1.038) | 0.626 |
| Walking independence (points) | −0.001 | 0.999 (0.868–1.149) | 0.988 |
OR, odds ratio; CI, confidence interval; HDS-R, Revised Hasegawa’s Dementia Scale; MRI, magnetic resonance imaging; SQ, semiquantitative; NF-κB, nuclear factor-κB; 25(OH) vitamin D, 25-hydroxy vitamin D; TRACP-5b, tartrate-resistant acid phosphatase 5b; GNRI, Geriatric Nutritional Risk Index; PCS, Pain Catastrophizing Scale; CSI, Central Sensitization Inventory; VAS, Visual Analog Scale; ADL, Activities of Daily Living; QOL, quality of life.
Hierarchical logistic regression analysis
| Variable | Partial regression coefficient | OR (95% CI) | |
|---|---|---|---|
| Model 1 | |||
| Age | −0.04 | 0.97 (0.90–1.03) | 0.318 |
| Sex | 0.24 | 1.27 (0.22–7.53) | 0.792 |
| BMI | −0.07 | 0.93 (0.77–1.13) | 0.469 |
| Cardiovascular disease | 2.51 | 12.27 (1.28–117.91) | 0.030 |
| Constant | 3.96 | ||
| Model 2 | |||
| Age | −0.04 | 0.96 (0.87–1.07) | 0.454 |
| Sex | 0.34 | 1.40 (0.19–10.46) | 0.744 |
| BMI | −0.13 | 0.88 (0.68–1.14) | 0.339 |
| Cardiovascular disease | 3.54 | 34.57 (2.53–471.74) | 0.008 |
| One leg standing movement control at 4 weeks | 1.98 | 7.25 (1.36–38.71) | 0.020 |
| PCS at 4 weeks | 0.10 | 1.11 (1.01–1.21) | 0.025 |
| Constant | 2.25 | ||
Model 1: χ2 p<0.05; discrimination rate=68.9%. Model 2: χ2 p<0.05; discrimination rate=75.0%.
OR, odds ratio; CI, confidence interval; BMI, body mass index; PCS, Pain Catastrophizing Scale.
Diagnostic performance
| Model | Cutoff value | Sensitivity | Specificity | PPV | NPV | Positive LR | Negative LR | AUC | Posterior probability |
|---|---|---|---|---|---|---|---|---|---|
| Model 1 | 0.42 | 0.63 | 0.75 | 0.70 | 0.69 | 2.54 | 0.48 | 0.73 | 0.70 |
| Model 2 | 0.61 | 0.68 | 0.91 | 0.88 | 0.75 | 8.18 | 0.34 | 0.87 | 0.88 |
Model 1: score=−0.04×age+0.24×sex–0.07×BMI+2.51×CVD. Model 2: score=−0.04×age+0.24×sex–0.07×BMI+2.51×CVD+1.98×one leg standing movement control at 4 weeks+0.10× PCS at 4 weeks.
PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; AUC, area under the curve; BMI, body mass index; CVD, cardiovascular disease; PCS, Pain Catastrophizing Scale.
Fig. 3Model 1: cutoff value of score when the state variable by receiver operating characteristic curve is set to vertebral collapse at >4 weeks post admission. AUC, area under the curve.
Fig. 4Model 2: cutoff value of score when the state variable by receiver operating characteristic curve is set to vertebral collapse at >4 weeks post-admission. AUC, area under the curve.